9.8819
Certara Inc 주식(CERT)의 최신 뉴스
Checking Back In On Certara: Unattractive Valuation (NASDAQ:CERT) - Seeking Alpha
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities - The Manila Times
Certara unveils advanced drug development simulator - Investing.com
Certara unveils advanced drug development simulator By Investing.com - Investing.com UK
Revolutionary AI Update: How Certara's New Simcyp Platform is Transforming Drug Development - Stock Titan
Proficio Capital Partners LLC Buys Shares of 13,856 Certara, Inc. (NASDAQ:CERT) - Defense World
Why Certara, Inc. (NASDAQ:CERT) Could Be Worth Watching - simplywall.st
At US$9.91, Is Certara, Inc. (NASDAQ:CERT) Worth Looking At Closely? - Yahoo Finance
Cautious Spending By Large Biopharma Client Dragged Certara (CERT) in Q3 - MSN
Certara Inc.: Is The Biosimulation & Software Growth Here To Stay? - Smartkarma
Commit To Buy Certara At $7.50, Earn 14.3% Annualized Using Options - Nasdaq
Raymond James Financial Inc. Takes Position in Certara, Inc. (NASDAQ:CERT) - Defense World
Certara, Inc. (NASDAQ:CERT) Receives $15.83 Consensus Price Target from Brokerages - Defense World
Certara, Inc. (NASDAQ:CERT) Shares Purchased by HighTower Advisors LLC - Defense World
Avantax Advisory Services Inc. Sells 17,660 Shares of Certara, Inc. (NASDAQ:CERT) - Defense World
Charles Schwab Investment Management Inc. Grows Holdings in Certara, Inc. (NASDAQ:CERT) - Defense World
PNC Financial Services Group Inc. Raises Stock Position in Certara, Inc. (NASDAQ:CERT) - Defense World
Amundi Raises Holdings in Certara, Inc. (NASDAQ:CERT) - Defense World
Atria Investments Inc Reduces Position in Certara, Inc. (NASDAQ:CERT) - Defense World
US Bancorp DE Has $101,000 Stock Position in Certara, Inc. (NASDAQ:CERT) - Defense World
(CERT) Technical Data - news.stocktradersdaily.com
Proficio Capital Partners LLC Takes Position in Certara, Inc. (NASDAQ:CERT) - Defense World
Certara’s SWOT analysis: ai-driven biosimulation firm faces growth challenges By Investing.com - Investing.com South Africa
Certara’s SWOT analysis: ai-driven biosimulation firm faces growth challenges - Investing.com Australia
Certara at Barclays Healthcare: Strategic Shift Toward Biosimulation - Investing.com India
Certara at Barclays Healthcare: Strategic Shift Toward Biosimulation By Investing.com - Investing.com South Africa
Certara Inc (NASDAQ: CERT) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register
Bank of New York Mellon Corp Purchases 1,253,385 Shares of Certara, Inc. (NASDAQ:CERT) - Defense World
23,568 Shares in Certara, Inc. (NASDAQ:CERT) Acquired by Private Advisor Group LLC - Defense World
Certara, Inc. (CERT): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions - citybiz
Certara announces leadership change in drug development By Investing.com - Investing.com South Africa
Certara announces leadership change in drug development - Investing.com India
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions -March 05, 2025 at 05:07 pm EST - Marketscreener.com
Certara Announces Leadership Change with Dr. Smith’s Departure - TipRanks
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions -March 05, 2025 at 04:16 pm EST - Marketscreener.com
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions -March 05, 2025 at 04:15 pm EST - Marketscreener.com
Can This Former IQVIA Executive Transform Certara's Drug Development Approach? - StockTitan
Principal Financial Group Inc. Has $5.66 Million Stock Position in Certara, Inc. (NASDAQ:CERT) - Defense World
Objective long/short (CERT) Report - Stock Traders Daily
Q2 Earnings Estimate for Certara Issued By William Blair - Defense World
Certara (NASDAQ:CERT) Price Target Raised to $13.00 - Defense World
Q1 Earnings Estimate for Certara Issued By Leerink Partnrs - Defense World
Rhumbline Advisers Has $2.96 Million Stock Holdings in Certara, Inc. (NASDAQ:CERT) - Defense World
Brokerages Set Certara, Inc. (NASDAQ:CERT) Price Target at $15.42 - Defense World
KeyBanc maintains Overweight rating on Certara shares with $15 target - Investing.com India
KeyBanc maintains Overweight rating on Certara shares with $15 target By Investing.com - Investing.com South Africa
자본화:
|
볼륨(24시간):